Category Archives: Biotechnology

NEW YORK, NY--(Marketwire -08/10/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) are up roughly 30 percent for the year, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Savient Pharmaceuticals, Inc. (SVNT) and PDL BioPharma Inc. (PDLI).

Access to the full company reports can be found at:

http://www.ParagonReport.com/SVNT

http://www.ParagonReport.com/PDLI

Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Savient Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Shares of company soared over 24 percent Wednesday after the company reported their second quarter loss decreased when compared with the year ago quarter.

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Net income for the second quarter of 2012 was $73.5 million, or $0.52 per diluted share, as compared with net income of $70.0 million, or $0.38 per diluted share, in the same quarter of 2011.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.paragonreport.com/disclaimer

See the rest here:
Savient Pharmaceuticals and PDL BioPharma Rise on Strong Earnings

NEW YORK, NY--(Marketwire -08/08/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) are up roughly 32 percent for the year, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on ISIS Pharmaceuticals, Inc. (ISIS) and Achillion Pharmaceuticals, Inc. (ACHN).

Access to the full company reports can be found at:

http://www.ParagonReport.com/ISIS

http://www.ParagonReport.com/ACHN

Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. The company reported revenues for the three months ended June 30, 2012 were $47.3 million, nearly double the total for the same period in 2011.

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including hepatitis C and resistant bacterial infections.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

http://www.paragonreport.com/disclaimer

Follow this link:
Biotech Industry Soaring in 2012 -- ISIS Pharmaceuticals Surges on Strong Results

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) today announced more than 100 speakers covering the latest in industrial biotechnology at the 2012 Pacific Rim Summit on Industrial Biotechnology and Bioenergy. The Summit will present four plenary sessions featuring international executives and academic leaders in industrial biotechnology October 10-12 at the Westin Bayshore in Vancouver, Canada.

Vancouver is an ideal location for this years conference with its fast-growing and successful life sciences and biotech industries and a robust forest biomass supply, said Brent Erickson, executive vice president for BIOs Industrial & Environmental Section. Our outstanding line-up of plenary sessions will highlight the growing biobased economy as we learn about advances in biofuels, renewable chemicals and synthetic biology. Industrial biotechnology can reduce dependence on foreign oil and also benefits consumers by revitalizing manufacturing and creating new opportunities for agriculture, generating jobs, making greener products and cleaner processes.

Plenary sessions include:

Status Report: The Synthetic Biology Pathway to Innovation in Fuels and Chemicals Wednesday, October 10, 12 2:15PM

Flying green: Why Airlines See a Bright Future in Biofuels Thursday, October 11, 8 9:30AM

Overcoming Regional Biomass Feedstock Supply Challenges with Public Policy and Science Thursday, October 11, 11:30AM 1:45PM

Biotechnology and Renewable Chemicals: The Future is Now Friday, October 12, 10AM 12PM

Now in its seventh year, the Pacific Rim Summit on Industrial Biotechnology and Bioenergy will address the latest issues in industrial biotechnology, including algae, advanced biofuels, biopolymers and bioplastics, dedicated energy crops, green chemistry, and synthetic biology. The annual Pacific Rim Summit is the original conference dedicated solely to growth of the industrial biotechnology sector in Asia and the Americas. Visit http://bio.org/pacrim.

In addition to the plenary sessions, the Pacific Rim Summit will bring you four breakout tracks with 24 sessions, designed to keep you on the cutting edge of industrial biotech. New in 2012- The Technical Presentations Track will feature 20 minute talks from academics, private sector scientists and researchers.

Originally posted here:
BIO Pacific Rim Summit to Address Innovation and Future of Advanced Biofuels and Biorefinery Development, Renewable ...

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) announces the 2nd annual BIO Convention in China, a partnering and investor conference that will bring together executives from biotechnology, pharmaceutical companies and investment firms from North America, Europe and Asia to meet and explore business opportunities with China's emerging biotech sector. The event will take place October 24-25, 2012 in Shanghai, China.

As China positions itself as a major global player in the international biotechnology arena, it has included biotechnology as one of the seven strategic priorities for scientific and technological development in its 12th Five-year Plan, said Alan Eisenberg, Executive Vice President of Emerging Companies and Business Development at BIO. "Through distinguished speakers, exemplary programming, compelling company presentations and exhibiting and networking opportunities, BIO China allows attendees to explore the vast business opportunities afforded by Chinas emerging biotech sector.

Dr. Michael Rosenblatt, M.D., executive vice president and chief medical officer for Merck, will provide one of two keynote addresses on October 25th. Directly following Dr. Rosenblatts keynote, Peng Wang, Ph.D., Chief Scientific Officer, Simcere will deliver his remarks. Governor Jon Huntsman, former U.S. Ambassador to China and Governor of Utah, will provide the third keynote address. Additional keynote speakers will be announced at a later date.

Panel sessions will highlight the latest issues and trends related to doing business in China. Preliminary program topics include the globalization of Chinese companies; innovation in generics and biosimilars; comparative legal systems in U.S., Europe and China; R&D trends in China; trends in cancer research and regulatory review in China.

BIO and the BIO China Advisory Committee set the event agenda and program. Advisory Committee members include:

BIO brings to China more than 15 years of experience in organizing international conferences for the biotech industry, including the BIO International Convention the global event for biotechnology. BIO is renowned for its successful business development, partnering and investor meetings in North America, Europe and Asia. Partnering at this conference will be powered by BIO One-on-One Partnering, an interactive environment to intelligently search, contact and schedule private meetings with potential partners and investors.

For more information on the BIO Convention in China, please visit here.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling innovations transforming our world. Subscribe to BIOtechNOW.

Excerpt from:
BIO Unveils Preliminary Program for the 2012 BIO Convention in China

LOS ANGELES--(BUSINESS WIRE)--

Puma Biotechnology, Inc. (PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at 12:45 p.m. EDT on Tuesday, August 14, at the Wedbush PacGrow 2012 Life Sciences Management Access Conference in New York.

A live webcast will be available on the Companys website at http://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.

Further information about Puma Biotechnology can be found at http://www.pumabiotechnology.com.

Forward-Looking Statements:

This press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic reports filed by the Company with the Securities and Exchange Commission from time to time. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

Read this article:
Puma Biotechnology to Present at Wedbush PacGrow Life Sciences Conference

NEW YORK--(BUSINESS WIRE)--

Proskauer has expanded its biotechnology patent litigation capabilities with the addition of Mary S. Consalvi as a Partner in the firms Patent Law Group. Based in New York, Ms. Consalvi is the former president and general counsel of NetBio Systems, Inc., a leading provider of rapid DNA analysis solutions located in Waltham, MA.

We are very fortunate to have a lawyer of Marys caliber joining our team, said Brendan ORourke and Robert Cleary, Proskauer Partners and co-Chairs of the firms Litigation Department. Not only is she a top-notch litigator, but she also has a keen understanding of patent and other business issues facing biotech companies based on her strong corporate and industry background.

Ms. Consalvi brings more than 20 years of experience to Proskauer. Prior to her tenure at NetBio, Ms. Consalvi served as Vice President and Chief Intellectual Property Counsel at biotechnology company Transkaryotic Therapies. Before that she was a partner in private practice at Howrey Simon Arnold & White and Lyon & Lyon.

"Having known Mary since we were partners together at Lyon & Lyon, I can't think of anyone better suited to help grow and expandourbiotech capabilities," said James Shalek, Proskauer Partner and co-head of its Patent Law Group. "Her extensive experience with NetBio shows she can build a business, as was also the case at Lyon & Lyon, where as that firm's first female partner, she was instrumental in the development and expansion of its San Diego biotechnology practice."

In addition to her experience at NetBio, where she was responsible for all aspects of the companys financing, business development and corporate and legal affairs, Ms. Consalvi is a leading intellectual property litigator, focusing on patent, trademark, copyright and trade secret law. She has counseled clients on freedom to operate analyses, opinion work and issues of patent validity, infringement and new-product introductions and represented companies with government grants and contracts. She is also experienced in matters related to partnerships/technology transfers between businesses and research institutions, including the drafting and negotiating of agreements covering such transfers.

Marys patent experience is very complementary to our current portfolio of work, and we see significant opportunities to broaden our biotech offering to clients, said Steven Bauer, Proskauer Partner and co-head of its Patent Law Group. She is a proven litigator who can provide strategic patent prosecution and associated licensing and transactional work for start-up and emerging biotech companies, as well as for later stage companies needing to build a patent portfolio.

About Proskauer

Founded in 1875, Proskauer is a global law firm widely recognized for its leadership in a variety of legal services provided to clients worldwide from offices in Beijing, Boca Raton, Boston, Chicago, Hong Kong, London, Los Angeles, New Orleans, New York, Newark, Paris, So Paulo and Washington, DC. Additional information about the firm, which has extensive experience in all areas of practice important to businesses, not-for-profit institutions and individuals, can be found at http://www.proskauer.com.

Read more:
Proskauer Broadens Biotech Patent Litigation Capabilities with New Partner in New York